Michael Jordan Fisch
Research Subjects
Michael Jordan Fisch has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Lynne I. Wagner
University of North Carolina, Chapel Hill, NC
17 shared publications - Norah Lynn Henry
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI
17 shared publications - Victor Tsu-Shih Chang
Department of Medicine, Hematology/Oncology Rutgers New Jersey School of Medicine Newark New Jersey USA
17 shared publications - Al Bowen Benson
Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
15 shared publications - Atif Shafqat
Heartland Cancer Research NCORP-Missouri Baptist Medical Center, Saint Louis, Missouri. 8
15 shared publications - Charles L. Loprinzi
Mayo Clinic, Rochester, MN
15 shared publications
Latest Publications
- 28 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500532
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11
PURPOSE: For the 10% of women diagnosed with cancer within reproductive age, reproductive health is a critical component of oncologic survivorship. Variable attention to guidelines pertaining to oncocontraception and oncofertility results in cancer care discordant with a patient's reproductive health goals, negatively affecting quality of life. This study aimed to determine if the Engendering Reproductive Health within Oncologic Survivorship (EROS) multilevel intervention improves reproductive health goal–concordant management within 3 months of cancer diagnosis. PATIENTS AND METHODS: EROS is a cluster randomized trial, with 17 US-based National Cancer Institute Community Oncology Research Program (NCORP) sites (including Minority/Underserved Sites) randomly assigned to receive either reproductive health intervention (RHI; eight sites) or standard of care (SC; nine sites). Eligible patients included patients age 15-55 years with a new cancer diagnosis. The multilevel intervention included reproductive health education and navigation components. The primary study outcome is reproductive health goal–concordant management. RESULTS: This ECOG-ACRIN trial enrolled 420 eligible patients from 17 NCORP sites, of which 379 had available data for the primary analysis (RHI n = 134; SC n = 245). Reproductive health goal–concordant management was achieved in 65.7% of women from RHI sites and 47.3% of women at SC sites (odds ratio [OR, RHI/SC], 2.07, 90% CI, 1.29 to 3.31). The intervention effect on reproductive health goal–concordant management was significant for women who had completed childbearing (OR [RHI/SC], 2.92 [90% CI, 1.65 to 5.17]; P = .002), whereas no such effect was observed among those who had not completed childbearing (OR [RHI/SC], 1.17 [90% CI, 0.72 to 1.89]; P = .60). CONCLUSION: The EROS intervention demonstrated marked improvement of reproductive health goal–concordant care, especially among patients who had completed childbearing. The multilevel EROS intervention demonstrates promise to improve adherence to national cancer guidelines at the complex intersection of reproductive health and cancer survivorship.
- 28 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500532
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11
PURPOSE: For the 10% of women diagnosed with cancer within reproductive age, reproductive health is a critical component of oncologic survivorship. Variable attention to guidelines pertaining to oncocontraception and oncofertility results in cancer care discordant with a patient's reproductive health goals, negatively affecting quality of life. This study aimed to determine if the Engendering Reproductive Health within Oncologic Survivorship (EROS) multilevel intervention improves reproductive health goal–concordant management within 3 months of cancer diagnosis. PATIENTS AND METHODS: EROS is a cluster randomized trial, with 17 US-based National Cancer Institute Community Oncology Research Program (NCORP) sites (including Minority/Underserved Sites) randomly assigned to receive either reproductive health intervention (RHI; eight sites) or standard of care (SC; nine sites). Eligible patients included patients age 15-55 years with a new cancer diagnosis. The multilevel intervention included reproductive health education and navigation components. The primary study outcome is reproductive health goal–concordant management. RESULTS: This ECOG-ACRIN trial enrolled 420 eligible patients from 17 NCORP sites, of which 379 had available data for the primary analysis (RHI n = 134; SC n = 245). Reproductive health goal–concordant management was achieved in 65.7% of women from RHI sites and 47.3% of women at SC sites (odds ratio [OR, RHI/SC], 2.07, 90% CI, 1.29 to 3.31). The intervention effect on reproductive health goal–concordant management was significant for women who had completed childbearing (OR [RHI/SC], 2.92 [90% CI, 1.65 to 5.17]; P = .002), whereas no such effect was observed among those who had not completed childbearing (OR [RHI/SC], 1.17 [90% CI, 0.72 to 1.89]; P = .60). CONCLUSION: The EROS intervention demonstrated marked improvement of reproductive health goal–concordant care, especially among patients who had completed childbearing. The multilevel EROS intervention demonstrates promise to improve adherence to national cancer guidelines at the complex intersection of reproductive health and cancer survivorship.
- Open Access
- 10 January 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (2) , 133-142
Association of Participation in Medicare's Oncology Care Model With Spending, Utilization, and Quality Outcomes Among Commercially Insured and Medicare Advantage Members
PURPOSE: The Oncology Care Model (OCM), a value-based payment model for traditional Medicare beneficiaries with cancer, yielded total spending reductions that were outweighed by incentive payments, resulting in net losses to the Centers for Medicare & Medicaid Services. We studied whether the OCM yielded spillover effects in total episode spending, utilization, and quality among commercially insured and Medicare Advantage (MA) members, who were not targeted by the program. PATIENTS AND METHODS: This observational study used administrative claims from a large national payer, yielding 157,189 total patients with commercial insurance or MA with solid malignancies who initiated 229,376 systemic anticancer therapy episodes before (2012-2015) and during (2016-2021) the OCM at 125 OCM-participating practices (a subset of total OCM practices) and a 1:10 propensity-matched set of 860 non-OCM practices. We used difference-in-differences analyses to assess the association between the OCM and total episode spending, defined as medical spending during a 6-month episode. Secondary outcomes included hospitalization and emergency department (ED) utilization and quality measures. RESULTS: From the pre-OCM to the OCM period, mean total episode payments increased from $45,504 in US dollars (USD) to $46,239 USD for OCM-participating practices, and increased from $50,519 USD to $58,591 USD for non-OCM practices (adjusted difference-in-differences –$6,287 USD [95% CI, –$10,076 USD to –$2,498 USD], P = .001). The OCM was associated with adjusted spending decreases for both high-risk (–$6,756 USD [95% CI, –$10,731 USD to –$2,781 USD], P = .001) and low-risk (–$4,171 USD [95% CI, –$7,799 USD to –$543 USD], P = .025) episodes. OCM-associated spending reductions were strongest for outpatient (–$5,243 USD [95% CI, –$8,589 USD to –$1,897 USD], P = .002) and infused/injected anticancer drug (–$3,031 USD [95% CI, –$5,193 USD to –$869 USD], P = .006) spending. There were no associations between OCM participation and changes in hospital or ED utilization nor quality of care. CONCLUSION: The OCM was associated with reductions in spending for nontargeted members, a spillover effect.
- 10 January 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (2) , 133-142
Open AccessAssociation of Participation in Medicare's Oncology Care Model With Spending, Utilization, and Quality Outcomes Among Commercially Insured and Medicare Advantage Members
PURPOSE: The Oncology Care Model (OCM), a value-based payment model for traditional Medicare beneficiaries with cancer, yielded total spending reductions that were outweighed by incentive payments, resulting in net losses to the Centers for Medicare & Medicaid Services. We studied whether the OCM yielded spillover effects in total episode spending, utilization, and quality among commercially insured and Medicare Advantage (MA) members, who were not targeted by the program. PATIENTS AND METHODS: This observational study used administrative claims from a large national payer, yielding 157,189 total patients with commercial insurance or MA with solid malignancies who initiated 229,376 systemic anticancer therapy episodes before (2012-2015) and during (2016-2021) the OCM at 125 OCM-participating practices (a subset of total OCM practices) and a 1:10 propensity-matched set of 860 non-OCM practices. We used difference-in-differences analyses to assess the association between the OCM and total episode spending, defined as medical spending during a 6-month episode. Secondary outcomes included hospitalization and emergency department (ED) utilization and quality measures. RESULTS: From the pre-OCM to the OCM period, mean total episode payments increased from $45,504 in US dollars (USD) to $46,239 USD for OCM-participating practices, and increased from $50,519 USD to $58,591 USD for non-OCM practices (adjusted difference-in-differences –$6,287 USD [95% CI, –$10,076 USD to –$2,498 USD], P = .001). The OCM was associated with adjusted spending decreases for both high-risk (–$6,756 USD [95% CI, –$10,731 USD to –$2,781 USD], P = .001) and low-risk (–$4,171 USD [95% CI, –$7,799 USD to –$543 USD], P = .025) episodes. OCM-associated spending reductions were strongest for outpatient (–$5,243 USD [95% CI, –$8,589 USD to –$1,897 USD], P = .002) and infused/injected anticancer drug (–$3,031 USD [95% CI, –$5,193 USD to –$869 USD], P = .006) spending. There were no associations between OCM participation and changes in hospital or ED utilization nor quality of care. CONCLUSION: The OCM was associated with reductions in spending for nontargeted members, a spillover effect.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S4: HAQ Scores at different time points (n=970).
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S4: HAQ Scores at different time points (n=970).
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S5: Association between clinicopathological variables and treatment discontinuation due to AIMSS.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S5: Association between clinicopathological variables and treatment discontinuation due to AIMSS.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S2: All Grades Treatment Related Toxicities (CTCAE v4).
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S2: All Grades Treatment Related Toxicities (CTCAE v4).
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S2: All Grades Treatment Related Toxicities (CTCAE v4).
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S2: All Grades Treatment Related Toxicities (CTCAE v4).
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S3: Off Treatment Reason.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S3: Off Treatment Reason.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S1: Representativeness of Study Participants
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S1: Representativeness of Study Participants
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S6: Allele frequency and Hardy-Weinberg equilibrium test result, by patient cohort.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S6: Allele frequency and Hardy-Weinberg equilibrium test result, by patient cohort.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S1: Representativeness of Study Participants
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S1: Representativeness of Study Participants